Phaseline

Targets › PPARG

PPARG (Peroxisome proliferator-activated receptor gamma): drug programs, companies and trials

13 programs from 13 companies in 38 trials: 11 Phase 2, 10 Phase 3, 10 Phase 1, 7 Phase 4; Oncology, Gastroenterology, Metabolic and endocrine; next expected readout Dec 2026.

Ligand-activated transcription factor that forms obligate heterodimers with the retinoic acid receptor and acts as a key regulator of biological processes, such as adipocyte differentiation, lipid metabolism, glucose homeostasis and beta-oxidation of fatty acids. Activated by lipid ligands: binds peroxisome proliferators, such as hypolipidemic drugs, and fatty acids, such as prostaglandin J2 metabolites. (UniProt, P37231)

Open in Phaseline: the race on PPARG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Dong Wha PharmaceuticalPioglitazone
Peroxisome proliferator-activated receptor gamma agonist
PPARGPhase 4Type2diabetes–
Zydus TherapeuticsSaroglitazar
Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor gamma agonist
PPARA, PPARGPhase 3Primary Biliary Cholangitis; Hepatic Impairment; Cholestatic Liver DiseaseDec 2026
Minoryx TherapeuticsLeriglitazone
Peroxisome proliferator-activated receptor gamma agonist
PPARGPhase 3Cerebral Adrenoleukodystrophy (cALD)May 2027
Inventiva PharmaLanifibranor (IVA337)
Peroxisome proliferator-activated receptor agonist
PPARG, PPARA, PPARDPhase 3NASH - Nonalcoholic SteatohepatitisSep 2027
Assistance Publique - Hôpitaux de ParisBezafibrate
Peroxisome proliferator-activated receptor agonist
PPARG, PPARA, PPARDPhase 3BPCDec 2027
The First Affiliated Hospital of Xiamen UniversityChiglitazar
Peroxisome proliferator-activated receptor agonist
PPARG, PPARA, PPARDPhase 2Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid LeukemiaDec 2026
University of Minnesotapioglitazone-metformin
PPAR-gamma agonist combined with AMP-activated protein kinase activator
PPARGPhase 2Oral LeukoplakiaJul 2027
AHS Cancer Control AlbertaMesalamine
Arachidonate 5-lipoxygenase inhibitor; Peroxisome proliferator-activated receptor gamma agonist; Cyclooxygenase inhibitor
ALOX5, PPARG, PTGS2, PTGS1Phase 2Immune-related Adverse EventAug 2027
Shanghai Jiao Tong University School of MedicineChiglitazar
Peroxisome proliferator-activated receptor agonist
PPARG, PPARA, PPARDPhase 2MASH - Metabolic Dysfunction-Associated SteatohepatitisDec 2030
Dan ZandbergRosiglitazone
Peroxisome proliferator-activated receptor-gamma (PPARγ) agonist
PPARGPhase 2MelanomaApr 2032
Ann-Sofie BackmanMesalamine
Arachidonate 5-lipoxygenase inhibitor; Peroxisome proliferator-activated receptor gamma agonist; Cyclooxygenase inhibitor
ALOX5, PPARG, PTGS2, PTGS1Phase 2Lynch SyndromeSep 2032
Flare TherapeuticsFX-909
PPARG transcription inhibitor (basal- and ligand-activated)
PPARGPhase 1Advanced Urothelial CarcinomaOct 2027
Boryung PharmaceuticalPioglitazone
Peroxisome proliferator-activated receptor gamma agonist
PPARGPhase 1Diabetes Mellitus; Diabete Mellitus; Infertility Treatment; Type 2 Diabetes …–

Conditions

Primary Biliary Cholangitis (3) BPC (2) Type 2 Diabetes (2) Hepatic Impairment (1) Cholestatic Liver Disease (1) Oral Leukoplakia (1) Advanced Urothelial Carcinoma (1) Melanoma (1) MASH - Metabolic Dysfunction-Associated Steatohepatitis (1) Relapsed or Refractory Acute Myeloid Leukemia (1) Acute Myeloid Leukemia (1) Diabetes Mellitus (1)

Modalities

small molecule (11), mixed (2)

Companies

Assistance Publique - Hôpitaux de Paris (1) Zydus Therapeutics (1) University of Minnesota (1) Flare Therapeutics (1) Dan Zandberg (1) Shanghai Jiao Tong University School of Medicine (1) The First Affiliated Hospital of Xiamen University (1) Boryung Pharmaceutical (1) Minoryx Therapeutics (1) Dong Wha Pharmaceutical (1) Ann-Sofie Backman (1) Inventiva Pharma (1) AHS Cancer Control Alberta (1)

Related targets

PPARA (5) PPARD (4) ALOX5 (2) PTGS2 (2) PTGS1 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.